Position in ACLX
as of Mar 31, 2026
· filed May 7, 2026
Position Value
$3,013,221
New position
Shares Held
26,243
first reported quarter
Ownership
0.045%
of shares outstanding
% of Portfolio
0.04%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Mar 31, 2026New York Life Investment Management LLC holds $61,218,953 across 21 Biotechnology names. ACLX ranks #5 (4.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
38,069 | $16,999,331 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
16,817 | $12,993,486 | |
| 3 | MRNA |
Moderna, Inc.
|
98,483 | $5,002,936 | |
| 4 | FOLD |
AMICUS THERAPEUTICS, INC.
|
306,400 | $4,430,544 | |
| 5 | ACLX |
Arcellx, Inc.
This page
|
26,243 | $3,013,221 | |
| 6 | INCY |
Incyte Corp
|
26,580 | $2,501,709 | |
| 7 | RVMD |
Revolution Medicines, Inc.
|
23,082 | $2,244,724 | |
| 8 | TECH |
BIO-TECHNE Corp
|
40,257 | $2,103,830 |
All Filings in ACLX
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $3,013,221 | 26,243 | Shares | Sole | 2026-05-07 | |
| No filing history on record for this holder in this stock. | ||||||